A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Pancreatic Cancer
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Terminated
Company research and development strategy adjustment
Other terminated trials from Shanghai Junshi Bioscience Co., Ltd.
- Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer · Phase PHASE1 · Jan 2024
- Advanced Cancer · Phase PHASE1 · Nov 2023
- Hepatocellular Carcinoma · Phase PHASE1/PHASE2 · Aug 2023
- Advanced Solid Tumors · Phase PHASE1 · Jun 2023
- Advanced or Metastatic Solid Tumors · Phase PHASE1 · Sep 2022
More terminations from Shanghai Junshi Bioscience Co., Ltd.
Other Advanced Pancreatic Cancer trials with similar outcome
This PHASE1 trial investigates Advanced Pancreatic Cancer and is currently terminated or withdrawn. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Jul 2025 — Present [monthly]
Terminated PHASE1
Status: Unknown → Terminated
-
Feb 2025 — Jul 2025 [monthly]
Unknown PHASE1
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Junshi Bioscience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .